Assembly Health Committee advances bills on abortion access, emergency reproductive care, syringe access and housing supports; most measures move to policy or财政

The California State Assembly Health Committee on April 8 advanced a set of bills touching reproductive health, public‑health harm reduction, substance‑use policy and Medi‑Cal benefits, moving the measures to subsequent policy or budget committees for further action.

Committee members voted to move bills including AB 54 (access to medication abortion protections), AB 551 (emergency‑department reproductive care pilot grants), AB 260 (safeguards for medication abortion and telehealth), AB 309 (removing sunset dates on syringe access laws), AB 536 (protecting colorectal cancer screening coverage), AB 804 (require DHCS to seek Medi‑Cal housing support benefit approval), AB 594 (student health insurance protections), AB 836 (midwifery workforce analysis), AB 1037 (updates to substance‑use disorder laws), AB 1418 (health‑care workforce reporting) and AB 1500 (maintenance and expansion of abortion.ca.gov). Many of the bills passed on voice votes or were ordered “do pass” and were referred to appropriations or other committees as recorded at the hearing.

Why it matters: the package bundles near‑term protections for medication abortion and expanded access to reproductive services with longer‑term public‑health measures. Committee testimony threaded two themes: (1) ensuring California preserves and expands access to evidence‑based reproductive care after federal shifts and legal challenges, and (2) aligning public‑health law with harm‑reduction practices and Medi‑Cal service design to reduce preventable illness and health system costs.

Key developments and testimony

AB 54 — Access to Safe Abortion Care Act: Assemblymember Maggie Krell, the bill’s author, and Tiffany Brokaw, deputy attorney general and legislative advocate (for Attorney General Rob Bonta), said AB 54 would shield manufacturers, distributors, pharmacies and authorized providers involved in the medication‑abortion supply chain from civil, criminal and professional discipline, and thereby protect access to mifepristone and misoprostol in California. Tyla Adams, reproductive justice manager at Black Women for Wellness Action Project, testified in support and urged the committee to consider equity impacts in access. Opposition testimony from Sophia Laurie, outreach director at California Family Council, argued the bill would permit mail distribution of abortion medication without in‑person medical evaluation and raised safety concerns citing FDA adverse‑event reports. The committee moved AB 54 to the judiciary committee on a voice vote.

AB 551 — Emergency department reproductive care pilot: Author Assemblymember (presenting) said AB 551 would create a pilot to award grants and technical assistance to emergency departments to provide evidence‑based, timely reproductive health care, including contraception and first‑trimester care. Dr. Anna Yap and Dr. Amy Mullen, emergency physicians, described emergency departments as the safety net where many pregnancies and urgent reproductive conditions are diagnosed and argued training and financial support would enable EDs to deliver contraception, definitive first‑trimester care and referrals. The bill was moved to appropriations.

AB 260 — Protections for medication abortion and telehealth: Sponsors including Angela Pontes (Planned Parenthood Affiliates of California) and Dr. Leah Koenig (UCSF) testified the bill would protect providers, pharmacies and clinics from disciplinary action for providing mifepristone and would preserve telehealth access that Californians use for medication abortion. Witnesses cited peer‑reviewed evidence and large cohort studies supporting the safety and effectiveness of telehealth medication abortion. The committee moved AB 260 to business and professions committee or the next referred policy committee as recorded.

AB 309 — Syringe access statutes (remove sunsets): The author said AB 309 would remove sunset dates that allow pharmacists to sell syringes without prescriptions and that possessing sterile syringes for personal use is not a crime. Public‑health witnesses, including Michelle Rivas (California Pharmacists Association) and Alex Kroll (epidemiologist, RTI), cited research linking syringe access to reductions in syringe sharing and infectious‑disease transmission; supporters included numerous public‑health, county and harm‑reduction groups. Opposition testimony by Ryan Sherman (California Narcotic Officers Association) and Sheriff Jeff Lykoff framed syringe distribution as a public‑safety concern; the committee moved AB 309 as “do pass” to appropriations.

AB 536 — Colorectal screening coverage protections: The author presented AB 536 as a technical protection to ensure continued no‑cost preventive colorectal screening coverage in California should federal guidance change. Proponents argued the measure would preserve existing screening access linked to improved health outcomes; it was moved forward.

AB 804 — Medi‑Cal housing support services: AB 804 would require the Department of Health Care Services to seek federal approval to make housing support services a covered Medi‑Cal benefit by March 31, 2026. Supporters said codifying the benefit would stabilize funding and allow a federal match (potentially up to 90%) for wraparound supportive housing services, which they described as cost‑effective investments that reduce emergency and acute care use. The committee moved the bill to appropriations.

AB 594 — Student health insurance billing and transparency: The bill would allow students to withdraw from student health insurance when no longer enrolled and require schools to notify students of year‑to‑year premium increases; the Department of Insurance testified as sponsor and a student gave a personal account of ongoing charges after withdrawing. The motion passed and the bill advanced.

AB 836 — Midwifery workforce analysis: AB 836 would commission a landscape analysis to assess midwifery education capacity, barriers and clinical placement needs to grow midwifery training in California. Testimony described workforce shortages, maternal‑health disparities and the potential of midwifery to expand access in underserved areas. The committee advanced the bill.

AB 1037 — Substance‑use disorder statutory updates: The bill (sponsor: author) would modernize statutes to expand access to evidence‑based, low‑barrier substance‑use treatment (including reducing procedural barriers that require 24‑hour abstinence for some programs) and to align statutes with current clinical practice and harm‑reduction approaches. Los Angeles County public health and multiple behavioral‑health groups supported the measure; law‑enforcement witnesses expressed public‑safety concerns. The committee passed AB 1037 as amended to the judiciary committee.

AB 1418 — Health workforce coverage reporting: The bill would require additional reporting on employer waiting periods and health‑insurance coverage for newly hired health‑care employees to inform workforce policy. Testimony from resident physicians and SEIU representatives cited residents’ financial challenges when benefits are delayed. The committee advanced the bill.

AB 1500 — Abortion.ca.gov maintenance and content: AB 1500 would designate a nonprofit to maintain abortion.ca.gov as a central, updated repository for reproductive‑health information for providers and the public and to counter disinformation. Sponsors argued federal websites and guidance have been altered or removed and California needs a trusted, stable source. Opposition witnesses highlighted parity concerns (for example, prenatal and maternal resources) and urged broader reproductive‑health investments; the committee moved the bill forward.

Votes at a glance (committee action recorded at hearing) - AB 54 (Krell) — Moved by Aguirre‑Curry; seconded by Schiavo. Outcome: Do pass to judiciary. (Committee recorded “do pass”/referred.) - AB 551 (Crow) — Outcome: Do pass to appropriations. (Moved and seconded; referred.) - AB 260 (Aguirre‑Curry) — Outcome: Do pass (referred to business & professions or next referred committee as recorded). - AB 309 (Zbur) — Outcome: Do pass to appropriations. - AB 536 (Patterson) — Outcome: Do pass to appropriations. - AB 804 (Wicks) — Outcome: Do pass to appropriations. - AB 594 (Solache) — Outcome: Do pass to appropriations. - AB 836 (Stephanie) — Outcome: Do pass to appropriations. - AB 1037 (Al‑Hawari) — Outcome: Do pass as amended to judiciary. - AB 1418 (Schiavo) — Outcome: Do pass to appropriations. - AB 1500 (Schiavo) — Outcome: Do pass to appropriations.

What supporters emphasized Supporters repeatedly cited evidence supporting medication abortion and telehealth, emergency‑department diagnostic burdens, research on syringe access reducing infectious disease transmission, and cost‑effectiveness of prevention and housing‑linked interventions. Several public‑health witnesses framed bills as preserving access in the face of federal actions or legal challenges (for example, potential federal rollbacks affecting medication approvals or federal website content).

What opponents emphasized Opponents raised safety and public‑safety concerns, particularly in testimony opposing medication‑abortion mail distribution and syringe or paraphernalia distribution. Some law‑enforcement witnesses and county sheriffs cautioned about community impacts, fire risk and messaging about illegal drug use; advocates for prenatal and maternal services urged parity for non‑abortion reproductive care.

What’s next Most measures were referred to appropriations or the relevant policy committees for further review, fiscal consideration or amendments. Several authors and sponsors asked the committee to accept coauthors and to continue technical work with stakeholders.

Evidence and excerpts Committee testimony cited peer‑reviewed studies, state public‑health evaluations, FDA reporting and program evaluations (for example, studies on telehealth abortion safety, pharmacy syringe‑sale pilots and the California Health Benefits Review Program analyses). Direct excerpts in the committee record include author statements and witness testimony described above.

Ending Committee action on April 8 advanced a broad set of public‑health and reproductive‑health measures that will now proceed through additional policy and fiscal review. Sponsors described the bills as steps to preserve access and align state law with current clinical practice; opponents called for additional safety and parity considerations.